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Thyroid involvement is a common condition that can be recorded during the natural 
course of different systemic rheumatic diseases, including the mixed cryoglobulinemia 
(MC) syndrome or cryoglobulinemic vasculitis. MC is triggered by hepatitis C virus (HCV) 
chronic infection in the majority of cases; it represents the prototype of autoimmune- 
lymphoproliferative disorders complicating a significant proportion of patients with 
chronic HCV infection. HCV is both hepato- and lymphotropic virus responsible for a 
great number of autoimmune/lymphoproliferative and/or neoplastic disorders. The com-
plex of HCV-related hepatic and extrahepatic manifestations, including MC and thyroid 
involvement, may be termed “HCV syndrome.” Here, we describe the prevalence and 
clinico-serological characteristics of thyroid involvement, mainly autoimmune thyroiditis 
and papillary thyroid cancer, in patients with HCV syndrome with or without cryoglobu-
linemic vasculitis.
Keywords: hepatitis C virus, thyroid, autoimmune thyroiditis, autoimmunity, cryoglobulinemia, cryoglobulinemic 
vasculitis, cancer, lymphoma
inTRODUCTiOn
Autoimmune thyroiditis (AT) includes a group of thyroid diseases whose etiopathogenesis is char-
acterized by chronic inflammatory response specifically self-directed against thyroid gland (1–3). 
Hashimoto’s thyroiditis and Graves’ disease represent the main pathophysiological and clinical 
entities of this single organ autoimmune disorder; nonetheless, subclinical thyroid dysfunctions 
should be considered in the disease spectrum (1, 2). Clinically, AT can lead to both hyper- and 
hypothyroidism, more often the latter, or it can produce slight, insidious variations of the TSH levels, 
without overt manifestations (1, 2). Presence of AT in the course of autoimmune systemic diseases, 
including mixed cryoglobulinemia (MC), is very frequent.
Mixed cryoglobulinemia is a small-vessel vasculitis due to vessel deposition of cryo- and non-
cryoprecipitable IgG–IgM immune complexes (ICs) and complement, which represent the main 
pathogenetic mechanism of disease manifestations, such as palpable purpura of the legs, skin 
ulcers, peripheral polyneuropathy, or glomerulonephritis; moreover, arthralgias, fatigue, sicca 
syndrome are frequently associated (4–7). The abnormal production of ICs is determined by B cell 
clone proliferation triggered by hepatitis C virus (HCV) in a small proportion of infected patients 
(Figure 1, left). Besides its well-known hepatic tropism, HCV is able to infect several cell types 
(including B  cells and thyrocytes); therefore, HCV lymphotropism can stimulate autoimmunity 
due to benign B-lymphocyte expansion or malignant B-cell non-Hodgkin’s lymphoma [(5–7); 
FigURe 1 | Etiopathogenesis of hepatitis C virus (HCV)-related disorders and HCV syndrome. Left: the etiopathogenesis of HCV syndrome includes both 
hepatic and extrahepatic disorders. They may develop through a multifactorial and multistep process that includes chronic HCV infection, other potential 
environmental/toxic triggers, genetically driven host predisposition (particularly HLA alleles, metabolic, and/or hormonal factors), and complex cellular and 
molecular alterations. From one side, we can observe HCV-driven immune-system alterations with prominent “benign” lymphoproliferation and autoantibody 
production, from the other side, deeper oncogenetic alterations leading to frank B-cell neoplasias and other malignancies (B-NHL, HCC, and papillary thyroid 
cancer). These different pathogenetic mechanisms are not mutually exclusive; during long-term follow-up, we can assist in the same HCV-infected patient to the 
appearance of different organ- and non-organ-specific autoimmune/neoplastic diseases, among which thyroid involvement. HCV antigens (core, envelope E2, 
NS3, NS4, NS5A proteins) may exert a chronic stimulus on the host immune system. Important pathogenetic steps include high-affinity binding between 
HCV-E2 and CD81 and consequent t(14;18) translocation with bcl-2 proto-oncogene activation, cross-reaction between particular HCV antigens and host 
autoantigens (molecular mimicry mechanism), and direct cell infection by HCV responsible for neoplastic cell transformation. The “benign,” often subclinical, 
B-cell proliferation with production of various autoantibodies, among which RF and cryo- and non-cryoprecipitable immune complexes may be frequently 
observed in chronically HCV-infected individuals. This condition may be the pathological substrate of various organ- and non-organ-specific autoimmune 
disorders, including thyroid involvement with/without mixed cryoglobulinemia (MC) syndrome or cryoglobulinemic vasculitis. Complicating malignancies can be 
observed in a small but significant percentage of patients, usually as a late complication of chronic HCV infection; moreover, both autoimmune and neoplastic 
disorders show a clinico-serological and pathological overlap. Right: schematic reproduction of the so-called “HCV syndrome” that encompasses the variety of 
HCV-related diseases. The majority of HCV-infected patients may remain totally asymptomatic or complicated by isolated liver involvement; however, a 
significant proportion of subjects may develop various extrahepatic manifestations that may include a variety of autoimmune/lymphoproliferative and neoplastic 
disorders; therefore HCV-positive patients are commonly referred to different specialists according the prevalent clinical manifestation(s). A number of HCV-
infected patients may be referred early to the rheumatologist because of mild clinical manifestations such as arthralgias/mialgias, sicca syndrome, and/or RF 
seropositivity. MC syndrome, also termed cryoglobulinemic vasculitis, represents the prototype of extrahepatic, immune-mediated systemic disorder 
characterized by multiple organ involvement. In this scenario, HCV-related thyroid involvement is one of the most frequent manifestations, isolated or in 
association with other extrahepatic disorders, mainly cryoglobulinemic vasculitis. RF, rheumatoid factor; NHL, non-Hodgkin’s lymphoma; HCC, hepatocellular 
carcinoma; PCT, porphyria cutanea tarda.
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Figure  1, left]. Therefore, HCV patients frequently present a 
variable combination of different organ and/or systemic autoim-
mune diseases and neoplasias. The proposed “HCV syndrome” 
encompasses the complex of both hepatic and extrahepatic 
disorders [(7); Figure 1, right] among which the MC, also called 
cryoglobulinemic vasculitis, is the pathophysiological and clini-
cal prototype (8).
As deeply described below, AT may be frequently found in 
HCV patients, with or without MC syndrome, suggesting an 
etiopathogenetic role of the virus in a subset of predisposed 
subjects (9–12).
THYROiD DiSeASe ASSOCiATeD  
wiTH HCv
Thyroid involvement is considered one of the most frequent 
endocrine disorders in association with chronic HCV infection, 
independently from the presence of MC (13); in particular, AT 
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may represent a frequent extrahepatic disease in the spectrum of 
HCV syndrome (4, 7, 13).
A large Italian population-based study published in 2004 
(14) investigated the prevalence of AT (including thyroid 
dysfunction) in a series of 630 HCV patients not treated with 
interferon (IFN)-alpha, compared with three control groups: 
389 individuals from an iodine-deficient area, 268 individuals 
from an area of iodine sufficiency, and 86 patients with chronic 
hepatitis B. HCV patients were more likely to have hypothy-
roidism (13%), anti-thyroglobulin antibodies (TgAb) (17%), 
and anti-thyroperoxidase antibodies (TPOAb) (21%) than the 
control groups (14).
A retrospective cohort study (15) analyzing data of users of US 
Veterans Affairs health-care facilities from 1997 to 2004 (146,394 
HCV-infected patients vs. 572,293 HCV negatives) found that 
thyroiditis risk was slightly increased (adjusted hazard ratio 1.13, 
95% CI 1.08–1.18; p < 0.001). It is supposable that the increased 
AT prevalence was underestimated because of 97% of cases were 
males, considering that both AT and hypothyroidism are associ-
ated with the female gender (12).
Other studies investigating the frequency of AT in smaller 
HCV patient cohorts were analyzed by Shen et  al. in a recent 
meta-analysis of the world literature on the topic (16). Totally, 
1,735 HCV-infected and 1,868 non-HCV subjects were pooled; 
prevalence of TgAb, TPOAb, and anti-thyroid microsomal 
antibody were 2.40-, 1.96- and 1.86-fold higher in HCV-positive 
subjects than in controls. Moreover, the hypothyroidism risk is 
3.10 (95% CI 2.19–4.40) in HCV-infected patients.
Up to the recent introduction of new antivirals, the mainstay 
of HCV treatment was the IFN-alpha in combination with ribavi-
rin. Several HCV patients developed AT as a consequence of IFN 
therapy, possibly due to the stimulation of antithyroid antibodies 
production in predisposed subjects (17). Frequently, IFN-related 
AT resolves within a few months (9).
THYROiD DiSeASe ASSOCiATeD  
wiTH MC
The coexistence of AT and MC has been reported in large cohort 
studies evaluating the clinico-serological characteristics of HCV-
infected patients (15, 18). However, a definite association between 
these two diseases was first investigated by an Italian case–control 
prospective study (19), including 93 patients affected by HCV-
related MC, 93 patients with isolated type C hepatitis, and 93 
age/sex-matched healthy subjects from the same geographical 
area as controls. AT, subclinical hypothyroidism, and the pres-
ence of isolated specific serum autoantibodies, i.e., TPOAb and/
or TgAb, were more frequent in the first group than the controls 
(35 vs. 16%, 11 vs. 2%, 31 vs. 12%, respectively). Moreover, 
higher frequency of AT was recorded among MC patients in 
comparison with hepatopathic patients (35 vs. 22%), with 
a significant high prevalence of TPOAb in MC (28 vs. 14%). 
Finally, hypothyroidism was associated with higher cryocrit 
and with the presence of other autoantibody positivity, as well 
as with longer MC duration, presence of proteinuria, or active 
hepatitis (19).
These findings showed that AT patients exhibited more pro-
nounced autoimmune phenomena and severity of MC, which 
represents the prototype of autoimmunity in HCV patients (7).
Moreover, a longitudinal study investigating the incidence of 
AT during the follow-up of 112 MC patients vs. 112 matched 
controls was recently carried out (20). Of interest, the appear-
ance of new cases of AT were evidenced during the course of 
HCV infection besides the observed AT at baseline; in par-
ticular, after a median of 67 and 96 months of follow-up in the 
two groups of HCV-positive patients with or without MC, AT 
was newly reported in 14 MC patients and in three controls; 
consequently, the overall prevalence of AT was increased up to 
33 and 16%, respectively. Moreover, hypothyroidism that was 
invariably absent at baseline developed in 11 MC patients and 
three controls (subclinical in 9/11 vs. 2/3, respectively), while 
no cases of Grave’s disease were registered. Interestingly, the 
logistic regression analysis confirmed that the appearance of 
hypothyroidism was related to female gender, a well-known risk 
factor for autoimmunity.
Noteworthy, even the prevalence of papillary thyroid cancer 
resulted higher in MC compared to hepatitis C patients; namely, 
the same study found two cases of cancer among MC patients, 
but none in hepatitis C and healthy controls (19). Subsequently, 
thyroid cancer was first reported also in patients with HCV 
infection regardless of the presence of other HCV-related 
manifestations (21); this finding supported the hypothesis of 
the oncogenic potential of HCV through the direct infection of 
thyrocytes with the possible contribution of the pathogenetic 
process responsible for AT (22, 23). Essentially, this latter 
reproduces the same multistep process already demonstrated 
for HCV lymphotropism with “benign” B-cell proliferation and 
subsequent lymphomagenesis (6, 7).
PATHOgeneSiS
Clinico-epidemiological studies largely demonstrated that 
chronic HCV infection is a relevant risk factor for the devel-
opment of a number of autoimmune or neoplastic diseases, 
including thyroid involvement, mainly AT (4, 5, 7–10). 
Considering this latter manifestation, an important contribute 
to understand the mechanisms involved in the pathogenesis of 
thyroid disorders was given by Blackard et al. (24), who demon-
strated that HCV may infect a human thyroid cell line (ML1), 
which presents the membrane expression of the important 
HCV receptor CD81.
Furthermore, several studies by our group reported the 
upregulation of the CXCL9, CXCL10, CXCL11 chemokines, as 
well as IL-6 in the serum of MC patients who also presented AT 
(25–29). Therefore, it could be hypothesized that HCV may lead 
toward chronic stimulation of the immune system (Figure 1, left), 
namely the T-helper 1 lymphocytes, which secrete interferon-
gamma and tumor necrosis factor-alpha, that in turn perpetuate 
the immune cascade increasing the levels of the chemokines cited 
above (Figure 2). Finally, the sustained activation of the immune 
system is at the basis of thyroid immune-mediated damage, lead-
ing to AT and other important disorders such as papillary thyroid 
cancer (21, 22).
FigURe 2 | Hepatitis C virus (HCV)-driven autoimmunity and thyroid involvement. Autoimmune thyroid involvement can be observed in a significant proportion of 
chronically HCV-infected patients; the possible etiopathogenetic mechanisms are schematically described in the figure. In genetically predisposed subjects, HCV 
thyroid infection (1) may lead to the upregulation of CXCL10 gene expression and secretion in thyrocytes (2); this chemokine may promote the recruitment of Th1 
lymphocytes, which secrete interferon-γ (IFNγ) and tumor necrosis factor-α (TNFα). These cytokines may in turn induce CXCL10 secretion by thyrocytes (3), thus 
perpetuating the immune-mediated pathogenetic cascade. The consequence may be the appearance of thyroid disorders; a comparable pathogenetic mechanism 
may be hypothesized for HCV-driven diabetes type 2.
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COnCLUSiOn
Autoimmune thyroiditis diagnosis is relatively simple and is 
based on typical laboratory and instrumental findings. The main 
autoantibodies of AT are the TPOAb and TgAb, while those 
directed against the TSH receptor are typical of Graves disease 
(1–3, 8). Histologically, lymphocytes infiltrate the thyroid 
parenchyma, even forming lymphoid follicles, progressively 
leading to parenchymal destruction and glandular fibrosis (3); 
anyway, thyroid biopsy is generally not required for the diagno-
sis. Instead, ultrasounds are usually important to support the 
AT diagnosis, identifying heterogeneous pattern of the gland, 
up to pseudo-nodular feature (1–3). The instrumental follow-
up is obviously important to precociously diagnose the cases of 
thyroid cancer.
Considering the relative feasibility of AT diagnosis using 
not expensive or invasive exams, all HCV patients, mainly 
if affected by MC, should undergo thyroid evaluation 
periodically.
In the majority of MC patients, AT is a silent part of the clinical 
picture; otherwise, hypothyroidism, more frequently subclinical, 
may develop (9, 19, 20). The standard hormone replacement 
therapy is indicated in symptomatic HCV-associated AT with/
without MC syndrome. HCV eradication is an important thera-
peutical/preemptive approach to several manifestations of HCV 
syndrome (30), including thyroid involvement, in particular the 
rare HCV-related papillary thyroid cancer.
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